Top Markets
Coin of the day
Generate Biomedicines, Inc. Generate Biomedicines, Inc.

Generate Biomedicines, Inc.

GENB
Kedudukan dalam Saham #6385
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative... Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
Harga Saham
$16.14
Modal Pasaran
$2.07B
Perubahan (1 hari)
-0.03%
Perubahan (1 tahun)
-
Negara
US
Perdagangan Generate Biomedicines, Inc. (GENB)

Kategori

Nisbah P/S bagi Generate Biomedicines, Inc. (GENB)
Nisbah P/S pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini Generate Biomedicines, Inc., nisbah P/S semasa (TTM) ialah 0. Pada akhir 2026, nisbah P/S syarikat ialah 0.
Sejarah nisbah P/S untuk Generate Biomedicines, Inc. dari 2026 hingga 2026
Nisbah P/S pada akhir setiap tahun
Tahun Nisbah P/S Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/S untuk syarikat atau pesaing yang serupa
Syarikat Nisbah P/S Perbezaan Nisbah P/S Negara
10.17 -
US
10.13 -
NL
2.95 -
AU
11.28 -
US
- -
CH